Type of Intervention: Medical products and medicines
Level of Jurisdiction: Federal
Overview: The U.S. Congress funded $61 million for the Food and Drug Administration (FDA) to support the development and review of vaccines and other countermeasures, as well as for monitoring and mitigating shortages to medical supply chains, as part of phase 1 legislation.
Phase 3 legislation provided an additional $11 billion for coronavirus vaccines, treatment, and diagnostics and an additional $80 million for the FDA to prioritize and expedite approval of coronavirus drugs.
Full details here: https://www.rpc.senate.gov/policy-papers/update-on-coronavirus-response